ALX Oncology
Jason Lettmann is a Board Member at ALX Oncology. Jason has also served as the CEO & Board Member at Promedior, Inc., Board Member at Ra Pharmaceuticals, and Board Member at Vapotherm. Jason has also worked with Lightstone Ventures, Second Genome, Inc., and Relievant Medsystems, Inc. in the past. Jason is currently a Board Member at Morgenthaler Ventures.
Jason Lettmann has a MBA from the University of Michigan - Stephen M. Ross School of Business and a BA in Pre-medicine/Psychology from the University of Iowa.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.